Q32 Bio公司今日宣布两项高层人事任命。José Trevejo，医学博士、哲学博士，正式出任首席医疗官一职。与此同时，Ellie Hershberger，药学博士，被任命为首席开发官。
这两位资深专家的加入，将为Q32 Bio的临床研发战略注入新的活力。Trevejo博士在药物开发领域拥有深厚积淀，其丰富的临床经验有望加速公司管线资产的推进。而Hershberger博士则在监管事务与产品开发策略方面颇具建树，她的到来将强化公司从实验室到市场的全链条转化能力。
Q32 Bio此举彰显了其强化领导团队、推动创新疗法惠及患者的坚定决心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.